July 2022—Caris Life Sciences introduced its Caris Assure liquid biopsy assay at the American Society of Clinical Oncology annual meeting in June.
Caris Assure is a blood-based molecular profiling assay that uses a novel circulating nucleic acids sequencing approach to analyze the whole exome and whole transcriptome of 22,000 genes, including loss of heterozygosity, microsatellite instability, and tumor mutational burden, from a blood sample. The assay includes characterization of somatic tumor alterations, somatic clonal hematopoiesis of indeterminate potential alterations, and identification of incidental germline findings. It also enables minimally invasive serial monitoring for detecting tumor heterogeneity and emergence of resistance mutations.
Caris Assure has demonstrated 99.99 percent specificity and more than 95 percent sensitivity for variant frequencies greater than 0.5 percent.
Caris Life Sciences, 888-979-8669